1
|
Maurer M, Casale T, Saini S, Ben-Shoshan M, Radin A, Akinlade B, Laws E, Mannent L. DUPILUMAB EFFICACY IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA BY IGE LEVEL: LIBERTY-CSU CUPID STUDY A. Ann Allergy Asthma Immunol 2022. [DOI: 10.1016/j.anai.2022.08.538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
2
|
Zhao Y, Wu L, Lu Q, Gao X, Zhu X, Yao X, Li L, Li W, Ding Y, Song Z, Liu L, Dang N, Zhang C, Liu X, Gu J, Wang J, Geng S, Liu Q, Guo Y, Dong L, Su H, Bai L, O'Malley JT, Luo J, Laws E, Mannent L, Ruddy M, Amin N, Bansal A, Ota T, Wang M, Zhang J. The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2021; 186:633-641. [PMID: 34358343 PMCID: PMC9298048 DOI: 10.1111/bjd.20690] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/05/2021] [Indexed: 11/28/2022]
Abstract
BACKGROUND Dupilumab is an antibody against interleukin 4 receptor α, used in treating atopic dermatitis (AD). OBJECTIVES To evaluate the efficacy and safety of dupilumab in adult Chinese patients with moderate-to-severe AD. METHODS In this randomized, double-blind, placebo-controlled, parallel-group, phase III study, conducted between December 2018 and February 2020, patients with AD received dupilumab (300mg) or placebo once every 2 weeks for 16 weeks, and were followed up for 12 weeks. The primary efficacy endpoint was the proportion of patients with both Investigator's Global Assessment (IGA) score of 0-1 and a reduction from baseline of ≥2 points at week 16. RESULTS Overall, 165 patients (mean age: 30.6 years; 71.5% male) were randomized: 82 to dupilumab and 83 to placebo. At week 16, 26.8% of patients in the dupilumab group and 4.8% of patients in the placebo group achieved the primary endpoint (difference, 22.0%; 95% confidence interval [CI], 11.37-32.65%; p<0.0001). Compared with placebo, higher proportions of patients in the dupilumab group achieved ≥75% reduction in the Eczema Area and Severity Index score (57.3% vs 14.5%; difference, 42.9%; 95% CI, 29.75-55.97%; p<0.0001) and had ≥3-point (52.4% vs 9.6%; difference, 42.8%; 95% CI, 30.26-55.34%; p<0.0001) and ≥4-point (39.0% vs 4.8%; difference, 34.2%; 95% CI, 22.69-45.72%; p<0.0001) reductions in weekly average daily peak daily pruritus numerical rating scale scores. The incidence of TEAEs during the treatment period was similar in the two groups. The incidence of conjunctivitis, allergic conjunctivitis, and injection site reaction was higher in the dupilumab group than in the placebo group. CONCLUSIONS In adult Chinese patients, dupilumab was effective in improving the signs and symptoms of AD and demonstrated a favorable safety profile.
Collapse
Affiliation(s)
- Y Zhao
- Peking University People's Hospital, Beijing, China
| | - L Wu
- Hangzhou First People's Hospital, Hangzhou, China
| | - Q Lu
- The Second Xiangya Hospital of Central South University, Changsha, China
| | - X Gao
- The First Hospital of China Medical University, Shenyang, China
| | - X Zhu
- Wuxi Second People's Hospital, Jiangsu, China
| | - X Yao
- Hospital for skin diseases, Institute of Dermatology, Chinese Academy of medical sciences, Nanjing, China
| | - L Li
- Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - W Li
- Huashan Hospital, Fudan University, Shanghai, China
| | - Y Ding
- Shanghai Skin Disease Hospital, Shanghai, China
| | - Z Song
- The Southwest Hospital of AMU, Chongqing, China
| | - L Liu
- Peking University First Hospital, Beijing, China
| | - N Dang
- Jinan Central Hospital, Jinan, China
| | - C Zhang
- Peking University Third Hospital, Beijing, China
| | - X Liu
- University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - J Gu
- Changhai Hospital of Shanghai, Shanghai, China
| | - J Wang
- Ningbo No.2 Hospital, Ningbo, China
| | - S Geng
- The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
| | - Q Liu
- Tianjin Medical University General Hospital, Tianjin, China
| | - Y Guo
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China
| | - L Dong
- Research & Development, Sanofi, Shanghai, China
| | - H Su
- Research & Development, Sanofi, Shanghai, China
| | - L Bai
- Research & Development, Sanofi, Shanghai, China
| | | | - J Luo
- Research & Development, Sanofi, Indianapolis, USA
| | - E Laws
- Research & Development, Sanofi, Bridgewater, USA
| | - L Mannent
- Research & Development, Sanofi, Paris, France
| | - M Ruddy
- Research & Development, Regeneron, New York, USA
| | - N Amin
- Research & Development, Regeneron, New York, USA
| | - A Bansal
- Research & Development, Regeneron, New York, USA
| | - T Ota
- Research & Development, Regeneron, New York, USA
| | - M Wang
- Medical, Sanofi China, Shanghai, China
| | - J Zhang
- Peking University People's Hospital, Beijing, China
| |
Collapse
|
3
|
White A, Fujieda S, Takabayashi T, Daizadeh N, Deniz Y, Rowe P, Mannent L, Amin N, Harel S, Li Y, Jagerschmidt A. P505 DUPILUMAB EFFECT ON TYPE 2 INFLAMMATION BIOMARKERS IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND NSAID-ERD. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
4
|
Peters A, Han J, Hellings P, Heffler E, Gevaert P, Bachert C, Xu Y, Chuang C, Mannent L, Guyot P, Kamat S. P506 INDIRECT TREATMENT COMPARISON OF BIOLOGICS USED FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPS. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
5
|
Gevaert P, Bachert C, Desrosiers M, Mullol J, Maspero J, Zhang M, Mao X, Kamat S, Khan A, Amin N, Staudinger H, Mannent L. P452 DUPILUMAB IMPROVES PATIENT-REPORTED OUTCOMES IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS AND COMORBID ASTHMA: SINUS-24/SINUS-52 TRIALS. Ann Allergy Asthma Immunol 2019. [DOI: 10.1016/j.anai.2019.08.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
6
|
Akinlade B, Guttman‐Yassky E, Bruin‐Weller M, Simpson E, Blauvelt A, Cork M, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis J, Mannent L, Hamilton J, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham N, Shumel B, Ardeleanu M, Wollenberg A. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019. [DOI: 10.1111/bjd.18276] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
7
|
Akinlade B, Guttman‐Yassky E, Bruin‐Weller M, Simpson E, Blauvelt A, Cork M, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis J, Mannent L, Hamilton J, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham N, Shumel B, Ardeleanu M, Wollenberg A. Dupilumab 临床试验中的结膜炎. Br J Dermatol 2019. [DOI: 10.1111/bjd.18288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
8
|
Akinlade B, Guttman‐Yassky E, de Bruin‐Weller M, Simpson E, Blauvelt A, Cork M, Prens E, Asbell P, Akpek E, Corren J, Bachert C, Hirano I, Weyne J, Korotzer A, Chen Z, Hultsch T, Zhu X, Davis J, Mannent L, Hamilton J, Teper A, Staudinger H, Rizova E, Pirozzi G, Graham N, Shumel B, Ardeleanu M, Wollenberg A. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181:459-473. [PMID: 30851191 PMCID: PMC6850316 DOI: 10.1111/bjd.17869] [Citation(s) in RCA: 241] [Impact Index Per Article: 48.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/05/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND Dupilumab blocks the shared receptor component for interleukin (IL)-4 and IL-13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate-to-severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate-to-severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment of moderate-to-severe asthma uncontrolled with their current medicines. AD trials have reported increased incidence of conjunctivitis for dupilumab vs. placebo. OBJECTIVES To characterize further the occurrence and risk factors of conjunctivitis in dupilumab clinical trials. METHODS We evaluated randomized placebo-controlled trials of dupilumab in AD (n = 2629), asthma (n = 2876), chronic rhinosinusitis with nasal polyps (CRSwNP) (n = 60) and eosinophilic oesophagitis (EoE) (n = 47). RESULTS In most AD trials, dupilumab-treated patients had higher conjunctivitis incidence than placebo controls. Higher baseline AD severity and previous history of conjunctivitis were associated with increased conjunctivitis incidence. Conjunctivitis was mostly mild to moderate. Most cases recovered or resolved during the treatment period; two patients permanently discontinued dupilumab due to conjunctivitis or keratitis. Common treatments included ophthalmic corticosteroids, antibiotics, and antihistamines or mast cell stabilizers. Most cases were diagnosed by the investigators. In asthma and CRSwNP trials, the incidence of conjunctivitis was lower for both dupilumab and placebo than in AD trials; dupilumab did not increase the incidence compared with placebo. In the EoE trial, no patients had conjunctivitis. CONCLUSIONS Conjunctivitis was more frequent with dupilumab treatment in most AD trials. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis was overall very low, and was similar for dupilumab and placebo. In AD, the incidence of conjunctivitis was associated with AD severity and prior history of conjunctivitis. The aetiology and treatment of conjunctivitis in dupilumab-treated patients require further study. What's already known about this topic? Ocular disorders, including allergic conjunctivitis, are common in patients with atopic dermatitis (AD). In most dupilumab AD trials, dupilumab-treated patients had higher conjunctivitis incidence than those receiving placebo. Most cases were mild to moderate and recovered or were recovering during study treatment; study treatment discontinuation due to conjunctivitis was rare. Conjunctivitis incidence was very low and similar for dupilumab and placebo in clinical trials in asthma, chronic rhinosinusitis with nasal polyps and eosinophilic oesophagitis. What does this study add? This analysis confirms and extends the results of the individual clinical trials. Baseline disease-related factors, including AD severity, prior conjunctivitis history and certain biomarkers (thymus and activation-regulated chemokine, IgE, eosinophils), were associated with increased incidence of conjunctivitis. Patients who responded well to dupilumab had reduced incidence of conjunctivitis. Further study is needed to elucidate the aetiology and treatment of conjunctivitis in dupilumab-treated patients with AD.
Collapse
Affiliation(s)
- B. Akinlade
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | - E. Guttman‐Yassky
- Department of DermatologyIcahn School of Medicine at Mount Sinai Medical CenterNew YorkNYU.S.A.
| | - M. de Bruin‐Weller
- Department of Dermatology & Allergology, University Medical Center UtrechtUtrechtthe Netherlands
| | - E.L. Simpson
- Department of DermatologyOregon Health & Science UniversityPortlandORU.S.A.
| | - A. Blauvelt
- Oregon Medical Research CenterPortlandORU.S.A.
| | - M.J. Cork
- Sheffield Dermatology ResearchDepartment of Infection, Immunity and Cardiovascular DiseaseThe University of Sheffield Medical SchoolSheffieldU.K.
| | - E. Prens
- Department of DermatologyErasmus MCRotterdamthe Netherlands
| | - P. Asbell
- Hamilton Eye InstituteUniversity of Tennessee Health Science CenterMemphisTNU.S.A.
| | - E. Akpek
- Wilmer Eye Institute at Johns Hopkins University School of MedicineBaltimoreMDU.S.A.
| | - J. Corren
- David Geffen School of Medicine at UCLALos AngelesCAU.S.A.
| | - C. Bachert
- ENT DepartmentGhent University HospitalGhentBelgium
- Department of Clinical Science, Intervention and Technology (CLINTEC)Karolinska InstitutetStockholmSweden
| | - I. Hirano
- Northwestern University Feinberg School of MedicineChicagoILU.S.A.
| | - J. Weyne
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | - A. Korotzer
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | - Z. Chen
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | | | - X. Zhu
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | - J.D. Davis
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | | | | | | | | | | | | | | | - B. Shumel
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | - M. Ardeleanu
- Regeneron Pharmaceuticals, Inc.TarrytownNYU.S.A.
| | | |
Collapse
|
9
|
Khan A, Vandeplas G, Huynh TMT, Joish VN, Mannent L, Tomassen P, Van Zele T, Cardell LO, Arebro J, Olze H, Foerster-Ruhrmann U, Kowalski ML, Olszewska-Ziaber A, Holtappels G, De Ruyck N, van Drunen C, Mullol J, Hellings PW, Hox V, Toskala E, Scadding G, Lund VJ, Fokkens WJ, Bachert C. The Global Allergy and Asthma European Network (GALEN rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology 2019; 57:32-42. [PMID: 29911211 DOI: 10.4193/rhin17.255] [Citation(s) in RCA: 104] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Chronic rhinosinusitis (CRS) is a common yet under-recognised chronic inflammatory disease of the nose and paranasal sinuses that is classified according to the presence (CRSwNP) or absence (CRSsNP) of nasal polyps. METHODS This paper reports the methodology and descriptive results of the Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort. We established a large CRS cohort within the GALEN consortium (European FP6 research initiative) to identify inflammatory endotypes, the natural disease course, and its impact on health-related quality of life (HRQoL). Detailed information on the impact of CRS on HRQoL, comorbidity incidence, objective disease measures, and medical and surgical treatments were collected. RESULTS This multicentre cross-sectional case-control study recruited 935 adults (869 eligible for analysis: 237 CRSsNP; 445 CRSwNP; 187 controls [reference group]). Comorbidities such as asthma, allergy, eczema, food allergy, urticaria, and chronic obstructive pulmonary disease were significantly more frequent in CRS patients. Nasal corticosteroids, antibiotics, and oral corticosteroids were the most common treatments. Significantly more CRSwNP patients reported previous sinonasal surgery. CONCLUSIONS This study provides detailed information that facilitates studying CRS and its main phenotypes. However, patient distribution of this study does not necessarily reflect disease distribution in the general population.
Collapse
Affiliation(s)
- A Khan
- Sanofi, Chilly Mazarin, France
| | | | | | - V N Joish
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| | | | | | | | | | - J Arebro
- Karolinska Institutet, Stockholm, Sweden
| | - H Olze
- Charite-Universitatsmedizin, Berlin, Germany
| | | | | | | | | | | | - C van Drunen
- Academic Medical Center, Amsterdam, the Netherlands
| | - J Mullol
- Hospital Clinic - IDIBAPS and Universitat de Barcelona, Barcelona, Spain
| | | | - V Hox
- University Hospitals Leuven, Leuven, Belgium
| | - E Toskala
- Temple University School of Medicine, Philadelphia, PA, USA
| | - G Scadding
- Royal National Throat, Nose and Ear Hospital, London, UK
| | - V J Lund
- Royal National Throat, Nose and Ear Hospital, London, UK
| | - W J Fokkens
- Academic Medical Center, Amsterdam, the Netherlands
| | | |
Collapse
|
10
|
Khan A, Huynh T, Kamat S, Mannent L, Tomassen P, Van Zele T, Cardell L, Arebro J, Olze H, Foerster-Ruhrmann U, Kowalski M, Olszewska-Ziaber A, Fokkens W, van Drunen C, Mullol J, Alobid I, Hellings P, Hox V, Toskala E, Scadding G, Lund V, Bachert C. IMPACT OF CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ON QUALITY OF LIFE BY SINO-NASAL SURGERY HISTORY. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.061] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
11
|
Fokkens WJ, Bachert C, Bernal-Sprekelsen M, Bousquet J, Djandji M, Dorenbaum A, Hakimi-Mehr D, Hendry S, Hopkins C, Leunig A, Mannent L, Mucha D, Onerci M, Pugin B, Toppila-Salmi S, Rowe P, Seys SF, Stimson S, Strzembosz A, Hellings PW. Rhinology Future Debates, an EUFOREA Report. Rhinology 2018; 55:298-304. [PMID: 29166426 DOI: 10.4193/rhin17.221] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
The first Rhinology Future Debates was held in Brussels in December 2016, organized by EUFOREA (European Forum for Research and Education in Allergy and Airways diseases). The purpose of these debates is to bring novel developments in the field of Rhinology to the attention of the medical, paramedical and patient community, in a highly credible and balanced context. For the first time in Rhinology, a peer to peer scientific exchange with key experts in the field of rhinology and key medical colleagues from leading industries let to a brainstorming and discussion event on a number of hot issues in Rhinology. Novel developments are presented by key experts from industry and/or key thought leaders in Rhinology, and then followed by a lively debate on the potential positioning of new developments in care pathways, the strengths and weaknesses of the novel development(s), and comparisons with existing and/or competing products, devices, and/or molecules. As all debates are recorded and distributed on-line with limited editing (www.rhinology-future.com), EUFOREA aims at maximizing the education of the target groups on novel developments, allowing a critical appraisal of the future and a more rapid implementation of promising novel tools, techniques and/or molecules in clinical practise in Europe. The next Rhinology Future debate will be held in Brussels in December 2017.
Collapse
Affiliation(s)
- W J Fokkens
- Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands
| | - C Bachert
- Upper Airways Research Laboratory, ENT Department, Ghent University, Belgium
| | - M Bernal-Sprekelsen
- Hospital Clinic, ENT-Department, Universidad de Barcelona Medical School, Spain
| | - J Bousquet
- University Hospital of Montpellier, Montpellier, France
| | - M Djandji
- Medical Affairs, Sanofi Genzyme, Cambridge, MA, USA
| | | | | | - S Hendry
- RVP and GM Europe, Entellus Medical Inc, Minneapolis, MN, USA
| | - C Hopkins
- Guys and St Thomas Hospital, and Kings College, London, UK
| | - A Leunig
- Rhinology Center Munich, Germany
| | - L Mannent
- Research and Development, Sanofi, Chilly Mazarin, France
| | - D Mucha
- Fiagon Ag Medical Technologie, Hennigsdorf, Germany
| | - M Onerci
- Department of Otorhinolaryngology, Hacettepe University, Ankara, Turkey
| | - B Pugin
- EUFOREA- European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium
| | - S Toppila-Salmi
- Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland
| | - P Rowe
- Global Medical Affairs, Immunology and Inflammation, Sanofi Genzyme, Bridgewater, NJ, USA
| | - S F Seys
- EUFOREA- European Forum for Research and Education in Allergy and Airway Diseases, Brussels, Belgium
| | | | - A Strzembosz
- International Medical Affairs, Medtronic ENT, Tolochenaz, Switzerland
| | - P W Hellings
- Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands and Department of Otorhinolaryngology, University Hospitals Leuven, Belgium
| |
Collapse
|
12
|
Katelaris CH, Maspero JF, Jayawardena S, Rowe P, Maroni J, Pirozzi G, Amin N, NMH G, Mannent L, Teper A. P58: DUPILUMAB EFFICACY AND EFFECT ON ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED PERSISTENT ASTHMA AND COMORBID CHRONIC RHINOSINUSITIS WITH OR WITHOUT NASAL POLYPS. Intern Med J 2017. [DOI: 10.1111/imj.58_13578] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- CH Katelaris
- Campbelltown Hospital and Western Sydney University; Sydney Australia
| | | | | | - P Rowe
- Sanofi; Bridgewater NJ USA
| | - J Maroni
- Regeneron Pharmaceuticals, Inc.; Tarrytown NY USA
| | | | - N Amin
- Regeneron Pharmaceuticals, Inc.; Tarrytown NY USA
| | - Graham NMH
- Regeneron Pharmaceuticals, Inc.; Tarrytown NY USA
| | | | | |
Collapse
|